---
title: "《回顧》恒指 2025 年上半年五大最強及最弱股份 (表)"
description: "恒指 2025 年上半年表現強勁，五大最強股份包括周大福 (+99.4%)、小米-W(+73.8%)、翰森製藥 (+72.2%)、中生製藥 (+64.4%) 和石藥 (+61.1%)。相對而言，五大最弱股份為比亞迪電子 (-24.4%)、金沙中國 (-21.8%)、信義光能 (-20.7%)、海爾智家 (-18.4%) 和美團-W(-17.4%)。整體來看，恒指在 2025 年上半年累計上漲 4,"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/246635060.md"
published_at: "2025-06-30T09:22:47.000Z"
---

# 《回顧》恒指 2025 年上半年五大最強及最弱股份 (表)

> 恒指 2025 年上半年表現強勁，五大最強股份包括周大福 (+99.4%)、小米-W(+73.8%)、翰森製藥 (+72.2%)、中生製藥 (+64.4%) 和石藥 (+61.1%)。相對而言，五大最弱股份為比亞迪電子 (-24.4%)、金沙中國 (-21.8%)、信義光能 (-20.7%)、海爾智家 (-18.4%) 和美團-W(-17.4%)。整體來看，恒指在 2025 年上半年累計上漲 4,012 點，漲幅達 20.0%，收於 24,072 點。

恒指 2025 年上半年五大最強股份：

股份│上半年股價變幅

周大福 (01929.HK)│+99.4%

小米-W(01810.HK)│+73.8%

翰森製藥 (03692.HK)│+72.2%

中生製藥 (01177.HK)│+64.4%

石藥 (01093.HK)│+61.1%

恒指 2025 年上半年五大最弱股份：

股份│上半年股價變幅

比亞迪電子 (00285.HK)│-24.4%

金沙中國 (01928.HK)│-21.8%

信義光能 (00968.HK)│-20.7%

海爾智家 (06690.HK)│-18.4%

美團-W(03690.HK)│-17.4%

總結恒指 2025 年上半年累升 4,012 點或 20.0%，收 24,072 點。

### Related Stocks

- [01929.HK - 周大福](https://longbridge.com/zh-HK/quote/01929.HK.md)
- [03692.HK - 翰森制藥](https://longbridge.com/zh-HK/quote/03692.HK.md)
- [01177.HK - 中國生物制藥](https://longbridge.com/zh-HK/quote/01177.HK.md)
- [00285.HK - 比亞迪電子](https://longbridge.com/zh-HK/quote/00285.HK.md)
- [06690.HK - 海爾智家](https://longbridge.com/zh-HK/quote/06690.HK.md)
- [00968.HK - 信義光能](https://longbridge.com/zh-HK/quote/00968.HK.md)
- [03690.HK - 美團-W](https://longbridge.com/zh-HK/quote/03690.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Hansoh Pharmaceutical Says Aumolertinib Mesylate Tablets Approved In EU As Monotherapy | Hansoh Pharmaceutical Group Company Ltd :AUMOLERTINIB MESYLATE TABLETS APPROVED IN EU AS MONOTHERAPY | [Link](https://longbridge.com/zh-HK/news/276401882.md) |
| Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as Monotherapy | Hansoh Pharmaceutical Group Company Limited announced that Aumolertinib Mesylate Tablets, known as Ameile in China, rece | [Link](https://longbridge.com/zh-HK/news/276480305.md) |
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/zh-HK/news/276393466.md) |
| Billionaire Henry Cheng’s units agree settlement with Hong Kong regulator | Business units owned by billionaire Henry Cheng's family have agreed to pay up to HK$1.5 billion to Giordano Internation | [Link](https://longbridge.com/zh-HK/news/276199191.md) |
| 15:02 ETDisrupting Chronic Cough: Julian Circo Brings AI to the World's Oldest Symptom | Julian Circo, Co-Founder of Hyfe, discusses on the Disruption Interruption podcast how his company is revolutionizing re | [Link](https://longbridge.com/zh-HK/news/276373106.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。